Nautilus Biotechnology (NAUT) vs Pacific Biosciences of California (PACB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nautilus Biotechnology (NAUT) has outperformed Pacific Biosciences of California (PACB) over the past year, gaining 126.3% versus a gain of 94.3%. Over five years, NAUT leads with a -65.7% price change compared with -88.8% for PACB. Pacific Biosciences of California is the larger company by market cap ($714.9 million vs $231.6 million), about 3.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NAUT | PACB |
|---|---|---|
| Share price | $1.82 | $2.30 |
| Market cap | $231.60M | $714.91M |
| 1-day change | -7.14% | -15.44% |
| YTD return | +0.51% | +45.45% |
| 1-year return | +126.33% | +94.29% |
| 5-year return | -65.67% | -88.85% |
| EPS (TTM) | $-0.45 | $-0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.31 | $3.44 |
| 52-week low | $0.82 | $1.07 |
| Distance from 52-week high | -57.77% | -33.14% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +110.44% | -6.09% |
| Average volume | 2.59M | 10.10M |
| Shares outstanding | 127.26M | 310.83M |
| Employees | 127 | 485 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Pacific Biosciences of California is about 3.1 times larger than Nautilus Biotechnology by market value ($714.91M vs $231.60M).
- NAUT has outperformed PACB by 32.0 percentage points over the past year.
About Nautilus Biotechnology
NAUT stock →Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.
Industrials · Biotechnology: Laboratory Analytical Instruments · 127 employees
About Pacific Biosciences of California
PACB stock →Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.
Industrials · Biotechnology: Laboratory Analytical Instruments · 485 employees
NAUT vs PACB FAQ
Which is bigger, Nautilus Biotechnology or Pacific Biosciences of California?
Pacific Biosciences of California (PACB) is larger, with a market capitalization of $714.91M compared with $231.60M for Nautilus Biotechnology (NAUT).
Which stock has performed better over the past year, NAUT or PACB?
NAUT returned +126.33% over the past 12 months, compared with +94.29% for PACB (price return, excluding dividends). Past performance does not predict future results.
Are Nautilus Biotechnology and Pacific Biosciences of California in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.